Briand, François Maupoint, Julie Brousseau, Emmanuel Breyner, Natalia Bouchet, Mélanie Costard, Clément Leste-Lasserre, Thierry Petitjean, Mathieu Chen, Li Chabrat, Audrey
...
Published in
Metabolism: clinical and experimental
Cardiovascular disease is the leading cause of deaths in nonalcoholic steatohepatitis (NASH) patients. Mouse models, while widely used for drug development, do not fully replicate human NASH nor integrate the associated cardiac dysfunction, i.e. heart failure with preserved ejection fraction (HFpEF). To overcome these limitations, we established a ...
Longo, Miriam Meroni, Marica Paolini, Erika Macchi, Chiara Dongiovanni, Paola
Published in
Metabolism: clinical and experimental
Nonalcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver dysfunctions and it is predicted to become the primary cause of liver failure and hepatocellular carcinoma. Mitochondria are highly dynamic organelles involved in multiple metabolic/bioenergetic pathways in the liver. Emerging evidence outlined that hepatic mitochondria ada...
Pietri, Léa Giorgi, Roch Bégu, Audrey Lojou, Manon Koubi, Marie Cauchois, Raphael Grangeot, Rachel Dubois, Noémie Kaplanski, Gilles Valéro, René
...
Published in
Metabolism: clinical and experimental
Few studies distinguished the independent role of overweight/obesity or their associated-comorbidities in the evolution towards severe forms of COVID-19. Obesity as a unifying risk factor for severe COVID-19 is an emerging hypothesis. The aim of this study was to evaluate whether excessive body weight per se, was a risk factor for developing a seve...
Katsiki, Niki Mantzoros, Christos
Published in
Metabolism: clinical and experimental
Hill, Michael A Sowers, James R Mantzoros, Christos S
Published in
Metabolism: clinical and experimental
While substantial evidence points towards obesity and associated cardiometabolic disorders being a major factor for poor outcomes in SARS-CoV2 infections (COVID-19), the complexity of the interplay between these two pandemics is becoming apparent. Indeed, as previously defined, this interaction between obesity and COVID-19 represents a 'syndemic' t...
Angelidi, Angeliki M Kokkinos, Alexander Katechaki, Eleftheria Ros, Emilio Mantzoros, Christos S
Published in
Metabolism: clinical and experimental
Blomdahl, Julia Nasr, Patrik Ekstedt, Mattias Kechagias, Stergios
Published in
Metabolism: clinical and experimental
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Whether moderate alcohol consumption plays a role for progression of NAFLD is disputed. Moreover, it is not known which tool is ideal for assessment of alcohol consumption in NAFLD. This study aimed to evaluate if moderate alcohol consumption assessed with...
Raposo, Helena F Forsythe, Patricia Chausse, Bruno Castelli, Júlia Z Moraes-Vieira, Pedro M Nunes, Valéria S Oliveira, Helena C F
Published in
Metabolism: clinical and experimental
The systemic function of CETP has been well characterized. CETP plasma activity reduces HDL cholesterol and thus increases the risk of atherosclerosis. Here, we investigated whether CETP expression modulate adiposity. Body adiposity and energy metabolism related assays and gene/protein expression were compared in CETP transgenic and non-transgenic ...
Fiorentino, Teresa Vanessa Monroy, Adriana Kamath, Subash Sotero, Rosa Cas, Michele Dei Daniele, Giuseppe Chavez, Alberto O Abdul-Ghani, Muhammad Hribal, Marta Letizia Sesti, Giorgio
...
Published in
Metabolism: clinical and experimental
In this study, we aimed to identify the determinants of mitochondrial dysfunction in skeletal muscle (SKLM) of subjects with type 2 diabetes (T2DM), and to evaluate the effect of pioglitazone (PIO) on SKLM mitochondrial proteome. Two different groups of adults were studied. Group I consisted of 8 individuals with normal glucose tolerance (NGT) and ...
Grespan, Eleonora Giorgino, Toni Natali, Andrea Ferrannini, Ele Mari, Andrea
Published in
Metabolism: clinical and experimental
The reduced action of incretin hormones in type 2 diabetes (T2D) is mainly attributed to GIP insensitivity, but efficacy estimates of GIP and GLP-1 differ among studies, and the negligible effects of pharmacological GIP doses remain unexplained. We aimed to characterize incretin action in vivo in subjects with normal glucose tolerance (NGT) or T2D ...
